Conclusions
Dihydroartemisinin-piperaquine was a promising alternative drug to
sulfadoxine-pyrimethamine for intermittent preventive treatment in
settings with high sulfadoxine-pyrimethamine resistance, especially at
4-6 weeks of administration. Based on real-world and other
epidemiological settings, more data will be needed to identify the risk
of adverse effects.